In this issue:
- Atezolizumab + bevacizumab in unresectable HCC (CHALLENGE)
- Adjuvant chemotherapy or chemoradiation in gallbladder cancer (ACCELERATE)
- Nivolumab + ipilimumab vs lenvatinib or sorafenib for unresectable HCC (CheckMate 9DW)
- SBRT + sorafenib in HCC (NRG Oncology/RTOG 1112)
- TACE combined with lenvatinib + pembrolizumab for unresectable HCC (LEAP-012)
- Modifiable risk factors for HCC in patients with MASLD
- Risk of HCC by steatotic liver disease and its subclassifications
- Disease aetiology does not affect atezolizumab + bevacizumab efficacy in HCC
- Use of GALAD score for detection of HCC in cirrhosis
- NC-AMRI versus ultrasound as surveillance modalities for HCC
Please login below to download this issue (PDF)